Tagged with IMS health

Pharma The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much greater emphasis on value demonstration and patient-level data. You have been General Manager at IMS Health for 8 years. During…

Pharma Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last interviewed you in 2009, you were busy reshaping the data-provision branch, strengthening the consultancy capabilities of the business and setting…

pharma IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his perspective about the Dutch healthcare and life sciences market, the challenges it poses and what companies can expect for the…

IMS IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014, what trends are shaping the industry as well as the moderate, yet positive outlook for 2015. How would you assess…

consulting IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such as the growing specialty drugs segment and shift towards the hospital sales channel. What changes have you seen in the…

Generics Al Z. Castro, General Manager of IMS Health Philippines, speaks about the ongoing challenges of bringing about awareness and acceptance of generics medicine to the local population, how this will affect IMS Health, and what their strategy is going forward over the next five years. IMS Health has previously classified…

Generics Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How have the markets in Denmark and Sweden evolves over the past five years, since the financial crisis started and austerity…

IMS Health Ireland Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time as a post-doctoral researcher for a Swedish biotech company that was contracting research services here in Ireland. I have since hung up my lab…

IMS Health Belgium Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS? My loyalty to IMS Health lies in the opportunities I have been presented during all these years. Although I have…

IMS Health Brazil We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a coherent story explaining the evolution since that time in the country’s pharmaceutical history? The one major factor influencing country growth…

IMS Health Turkey Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS decide to separate Turkey from these regions ? Every third or fourth year, according to the growth of each country…

IMS Health Chile IMS was recently acquired by two investment funds, how has this affected the operations of the company and what changes did it bring in the Chilean context? So far, the acquisition has been beneficial for our Chilean operations. We expect bigger transformations to take place starting January 1st 2011, and…